drugset / Trial / NCT00444964

Growth Hormone Use in Adults With Prader-Willi Syndrome

NCT00444964

Phase 3 Completed 11 enrolled Children's Mercy Hospital Kansas City
NaSingle-groupOpen-labelDiagnostic

Summary

The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss of effects after cessation of treatment for at least 12 months.

Timeline

Start
2005-04
Primary completion
2012-01-01
Completion
2012-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.0125 mg/kg

Indications